Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News ARS Pharmaceuticals Inc. SPRY

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SPRY)

Fundamentals Snapshot (NDAQ:SPRY)

Current News (NDAQ:SPRY)

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

GlobeNewswire November 10, 2022

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

GlobeNewswire November 8, 2022

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, RMED, RCOR, and BTRS Shareholders About Its Ongoing Investigations

PR Newswire October 27, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, POSH, PBFX, RNWK, AERI

PR Newswire October 25, 2022

Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

Business Wire October 21, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, SBTX, COWN, JVA, HVBC

PR Newswire October 20, 2022

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX

Business Wire October 14, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FBMS, SBTX, RFP, COWN

PR Newswire October 13, 2022

SHAREHOLDER ALERT: Weiss Law Reminds MNRL, ECOM, SBTX, and IRBT Shareholders About Its Ongoing Investigations

PR Newswire October 6, 2022

Opinion & Analysis (NDAQ:SPRY)

No current opinion is available.

Bullboard Posts (NDAQ:SPRY)